Aastrom Biosciences Inc. (ASTM) Stock Quote

Detailed Quote for Aastrom Biosciences Inc. (ASTM) 
$ 2.00 0.00 (0.00%) Volume: 207.45 k 4:00 PM EST Feb 3, 2012
Today 5d 1m 3m 1y more
Last Price
2.00
Change $
Change %
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
2.02
High
2.02
Low
1.97
Prev Close
2.00
Last Trade
4:00
Volume
207.45 k
52 Wk Hi
3.47
52 Wk Low
1.75
Market Cap
77.27 m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
38,635,225
EPS (TTM)
-0.88
PE Ratio
N/A
Exchange
NSC
News and Media for Aastrom Biosciences Inc.  (ASTM) 
Sector News | Topic News
News for ASTM
Tue, Jan 24, 2012
8:20 AM Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry - Marketwire
Mon, Jan 09, 2012
8:20 AM Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012 - Marketwire
Tue, Nov 22, 2011
4:07 PM Aastrom Biosciences to Present at Piper Jaffray 23rd Annual Health Care Conference in New York City - Globe Newswire
Wed, Nov 16, 2011
8:16 AM Breakthrough Stem Cell Therapy From Aastrom Biosciences and NeoStem Begins to Gain Ground - Marketwire
Mon, Nov 14, 2011
11:15 AM Aastrom Reports Positive 12-Month Results from the RESTORE-CLI Phase 2 Clinical Trial for Ixmyelocel-T in Patients with Critical Limb Ischemia - Globe Newswire
Fri, Nov 11, 2011
4:05 PM Aastrom Biosciences to Hold Research and Development Day Review for Investors on November 17, 2011 - Globe Newswire
Tue, Nov 08, 2011
4:05 PM Aastrom Biosciences Reports Third Quarter 2011 Financial Results - Globe Newswire
Thu, Nov 03, 2011
9:05 AM New York Academy of Sciences Symposium on Advances in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular Diseases to Feature Aastrom Biosciences - Globe Newswire
Tue, Nov 01, 2011
4:05 PM Final 12-Month Results From the Aastrom RESTORE-CLI Phase 2b Clinical Trial to be Presented at the American Heart Association Scientific Sessions 2011 on Monday, November 14, 2011 - Globe Newswire
Mon, Oct 31, 2011
4:05 PM Webcast Alert: Aastrom to Host Third Quarter 2011 Investor Call on Tuesday, November 8, 2011 - Globe Newswire
Thu, Oct 13, 2011
4:11 PM Aastrom Appoints Brian Gibson as Vice President, Finance - Globe Newswire
Mon, Oct 03, 2011
9:00 AM Aastrom Granted European Composition-of-Matter Patent for Ixmyelocel-T - Globe Newswire
Fri, Sep 23, 2011
9:00 AM Aastrom to Present at the Sixth Annual JMP Securities Healthcare Conference - Globe Newswire
Mon, Sep 19, 2011
9:00 AM Aastrom Announces Positive 12-Month Safety and Efficacy Data From IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy - Globe Newswire
Fri, Sep 16, 2011
9:00 AM Aastrom Chief Scientific Officer Ronnda Bartel, PhD, to Present at the Cell Therapy Commercialization Summit - Globe Newswire
Wed, Sep 14, 2011
9:00 AM Aastrom to Present 12-Month Data From the IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy - Globe Newswire
Thu, Sep 08, 2011
9:00 AM Aastrom to Present at the 13th Annual Rodman & Renshaw Healthcare Conference - Globe Newswire
Thu, Sep 01, 2011
9:01 AM Aastrom to Present at the Stifel Nicolaus Healthcare Conference - Globe Newswire
Mon, Aug 15, 2011
4:01 PM Aastrom Biosciences Reports Operating Results for the Quarter and Six Months Ended June 30, 2011 - Globe Newswire
Thu, Aug 11, 2011
4:01 PM Aastrom Announces Adoption of Shareholder Rights Plan - Globe Newswire
More News for ASTM >>

Tags for Aastrom Biosciences Inc.

Research stocks or mutual funds related to Aastrom Biosciences Inc. by keywords or tags. Find companies that have a similar focus to ASTM. The keywords below have been associated to ASTM by either user submission or electronic means.

stem cells information guided tissue regeneration king report on corporate governance history of embryonic stem cell research cloning stem cells human embryonic stem cell stem cell research paper tissue repair neural stem cell stem cell product tissue engineering stem cells china stem cell biology stem cells diabetes embryonic stem cells Biological Products embryo stem cell research save stem cells stem cell tech corporate governance practices stem cell information corporate governance issues define corporate governance board of directors role stem cell news stem cell research debate stem cell research and diabetes investments corporate governance disclosure embryo stem cell board of directors governance directors duties stem cell research articles for stem cell research stem cells therapy Drugs corporate governance hong kong stem cell transplantation stem cell board of directors compensation bone graft dental bone grafting mouse embryonic stem cells embryo stem cells bone substitute stem cell legislation stem cell research legislation stem cell spinal cord injury stem cell research ethics Healthcare

 

NYE - Equity | NYE - ETF | AMX - Equity | AMX - ETF | NSD - Equity | NSD - ETF
NMF - ETF | NMF - Money Market Fund | NMF - Mutual Fund | OTC - Equity | OTO - Equity | OTO - ETF | OTO - Mutual Fund
CNQ - Equity | CBO - Equity | BDM - Equity | TSX - Equity | TSX - ETF | TSX - Mutual Fund | TSV - Equity | TSV - Mutual Fund

Dow Jones Composite Index | Dow Jones Industrial Avg | Dow Jones Transportation Avg | Dow Jones Utiliy Index | NASDAQ 100
Russell 1000 | Russell 2000 | Russell 3000 | Russell Microcap | Russell Midcap | S&P 500 | S&P MidCap 400 | S&P/TSX 60 | S&P/TSX MidCap

Recently Added Symbols   Firms   Find Financial Advisors

Advisors by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

RIAs by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tags: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Insiders: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.

Copyright © 2010 InvestorPoint.com All rights reserved.